Uncategorized
Rhopressa fails to meet primary efficacy endpoint of non inferiority to timolol
Despite failing to meet its primary endpoint of non-inferiority to timolol, the glaucoma medication Rhopressa compared well with timolol on most key metrics, according to Vincente Anido Jr., PhD, chairman and CEO of Aerie Pharmaceuticals.Anido delivered 90-day efficacy results of the initial phase 3 Rocket 1 clinical trial during a company-sponsored conference call.